CASI Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CASI Pharmaceuticals, Inc.
Pfizer’s acquisition of Arena without FTC intervention and Hikma’s acquisition of Custopharm with one product divestiture shows the commission is bound by anticompetitive facts of a deal. A more controversial merger may not get through, former FTC attorney says.
The SC Johnson brand is providing full refunds to consumers who purchased the chamomile verbena Bubble Bath products, which may contain a bacterium that is potentially harmful to the immunocompromised and those with broken or irritated skin, “such as diaper rash.”
Plus deals involving Shionogi/NEC, Ji Xing/LENZ, Kyowa Kirin/Ardelyx, CR Pharma/Everest Medicine and Dr Reddy’s/Novartis.
Stakeholders across medtech industry submit comments on FDA's itsplans to help companies looking to keep their EUA products on the market post-pandemic.
- Other Names / Subsidiaries
- EntreMed, Inc.
- Miikana Therapeutics, Inc.